News

04.20.2022  |  News

Flagship-backed 'gene-writing' startup Tessera raises $300M

From Boston Business Journal

04.19.2022  |  News

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

From Business Wire

04.19.2022  |  News

Finance Watch: Tessera Secures $300m-Plus To Write New Genes

From Scrip

04.19.2022  |  News

Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing

From Endpoints News

04.19.2022  |  News

Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech

From Bloomberg

04.19.2022  |  News

April 19 Quick Takes: Flagship-founded Tessera raises $300M from broad syndicate

From BioCentury

04.19.2022  |  News

Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms

From Fierce Biotech

02.14.2022  |  News

Navigating Recruitment and Hiring Amid ‘The Great Resignation’: Bec Lillie, Chief Human Resources Officer, Tessera

From Pharmaceutical Executive

01.28.2022  |  News

These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Here's how they could upend biotech in 2022

From Business Insider

01.05.2022  |  News

Novel Gene Editing Systems Come Into Their Own

From Genetic Engineering & Biotechnology News

01.05.2022  |  News

Scientists Race to Make Really Big Changes to Your Genes

From Barron's

12.15.2021  |  News

How technology could transform drug research in 2022

From Pharmaceutical Technology

12.08.2021  |  News

Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing™ Technology as New Category in Genetic Medicine

From Business Wire

11.03.2021  |  News

Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments

From Biopharma Dive

11.03.2021  |  News

Cystic Fibrosis Foundation, Flagship Pioneering team up to develop new treatments for deadly disease

From Boston Globe

11.03.2021  |  News

Fleet of Flagship biotechs will get up to $110M for new cystic fibrosis treatments

From FierceBiotech

11.03.2021  |  News

Flagship and the Cystic Fibrosis Foundation team up on a novel research pact to chase down potential cures

From Endpoints News

11.03.2021  |  News

Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship’s Pioneering Medicines to Treat Cystic Fibrosis

From Business Wire

07.14.2021  |  News

Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0

From Endpoints News

07.14.2021  |  News

Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Team

From Business Wire

06.15.2021  |  News

Gene writing: The future of genetic medicine?

From Pharmaceutical Technology

06.15.2021  |  News

Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors

From Business Wire

04.07.2021  |  News

Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development

From Business Wire

01.12.2021  |  News

Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure disease

From FierceBiotech